Arcturus Therapeutics RSI Overbought, KDJ Death Cross Triggered on 15min Chart

As of August 7th, 2025 at 9:45am, Arcturus Therapeutics's 15-minute chart has reached an RSI Overbought status, accompanied by a KDJ Death Cross. This indicates that the stock price has experienced a rapid increase, exceeding the fundamental support, and its momentum is shifting towards a downward trend, with potential for further depreciation.

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), a late-stage clinical messenger RNA medicines and vaccine company, is expected to report a significant decrease in quarterly revenue when it releases its financial results on August 4, 2025 [1]. Analysts predict a 55.0% fall in revenue to $22.435 million from $49.86 million a year ago, with a mean estimate of a 90 cents per share loss [1].

The current consensus among analysts is overwhelmingly positive, with 12 "strong buy" or "buy" ratings and no "hold," "sell," or "strong sell" ratings. The mean earnings estimate from analysts has remained unchanged over the past three months, and the median 12-month price target stands at $48.00, about 74.6% above the last closing price of $12.21 [1].

Technical indicators, however, suggest a potential market correction. As of August 7th, 2025 at 9:45am, Arcturus Therapeutics' 15-minute chart has reached an RSI Overbought status, accompanied by a KDJ Death Cross. This indicates that the stock price has experienced a rapid increase, exceeding fundamental support, and its momentum is shifting towards a downward trend, with potential for further depreciation [2].

Several hedge funds have recently increased their stakes in Arcturus Therapeutics, reflecting positive institutional sentiment. Byrne Asset Management LLC, US Bancorp DE, Virtus ETF Advisers LLC, KLP Kapitalforvaltning AS, and Strs Ohio have all increased their holdings in the company [2].

Despite the positive sentiment from analysts and institutional investors, the technical indicators suggest caution. Investors should closely monitor the company's earnings report and market trends to make informed decisions.

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TT2R6:0-arcturus-therapeutics-holdings-inc-expected-to-post-a-loss-of-90-cents-a-share-earnings-preview/
[2] https://www.marketbeat.com/instant-alerts/arcturus-therapeutics-holdings-inc-nasdaqarct-given-average-recommendation-of-buy-by-brokerages-2025-08-07/